Literature DB >> 29024382

Comparison of outcomes with surgical cut-down versus percutaneous transfemoral transcatheter aortic valve replacement: TAVR transfemoral access comparisons between surgical cut-down and percutaneous approach.

Brandon C Drafts1, Charles H Choi1, Kunal Sangal1, Michael W Cammarata1, Robert J Applegate1, Sanjay K Gandhi1, Edward H Kincaid2, Neal Kon2, David X Zhao1.   

Abstract

OBJECTIVES: The objective is to compare the short-term (30 days) and late (12 months) vascular adverse events in patients undergoing transfemoral (TF)-transcatheter aortic valve replacement (TAVR) by surgical cut-down (SC) vs. percutaneous (PC) approaches.
BACKGROUND: Programs continue to utilize both approaches in TF-TAVR. There are limited data comparing outcomes by SC vs. PC approaches and long-term effects of endovascular intervention facilitated hemostasis on late vascular adverse events.
METHODS: A total of 146 men and women aged 79.7 ± 10.0 years with severe aortic stenosis deemed extreme or high risk for surgery underwent TAVR via TF access. 61 had SC and 85 had PC approaches. Valve Academic Research Consortium (VARC-2) outcomes were assessed at an average of 12.1 months after TAVR.
RESULTS: Hospital length of stay (LOS) post-TAVR was shorter for the PC group compared to the SC group (5.1 ± 3.9 vs. 8.2 ± 6.6 days; P < 0.001). More patients were discharged directly to home in the PC than the SC group (85.9% vs. 68.9%, P < 0.05). At 30 days, there were 13/61 (21.3%) and 16/85 (18.8%; P < 0.05) of any vascular events, and 2/61 (3.3%) and 2/85 (2.4%; P = 0.73) major vascular events in the SC and PC groups, respectively. There was no difference in all-cause mortality between the SC (14/61; 23%) and PC groups [17/85 (20%); P = 0.34]. There was no difference in any [4/33 (12%) vs. 3/43 (7%); P = 0.84] or major vascular adverse events [1/33 (3%) vs. 1/43 (2%); P = 0.79] in subjects that underwent adjunctive endovascular intervention compared to those who did not, respectively. There were no statistically significant univariate or multivariate predictors of any vascular event at 12 months when comparing SC to PC groups.
CONCLUSION: For TF TAVR, the PC approach, when compared to the SC approach, is associated with a shorter hospital LOS and higher rate of direct discharge to home with similar risk of vascular complications, late vascular adverse events, and all-cause mortality at 12 months.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Transcatheter valve implantation; aortic valve disease percutaneous intervention; comparative effectiveness/patient centered outcomes research; vascular complications

Mesh:

Year:  2017        PMID: 29024382     DOI: 10.1002/ccd.27377

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

Review 1.  Strategies for Facilitating Totally Percutaneous Transfemoral TAVR Procedures.

Authors:  Amnon Eitan; Hussein Sliman; Avinoam Shiran; Ronen Jaffe
Journal:  J Clin Med       Date:  2022-04-09       Impact factor: 4.964

Review 2.  Transcatheter Aortic Valve Replacement Programs: Clinical Outcomes and Developments.

Authors:  Vinayak Kumar; Gurpreet S Sandhu; Charles M Harper; Henry H Ting; Charanjit S Rihal
Journal:  J Am Heart Assoc       Date:  2020-04-17       Impact factor: 5.501

3.  Sex differences in patients undergoing transcatheter aortic valve replacement in Asia.

Authors:  Paul T L Chiam; Kentaro Hayashida; Yusuke Watanabe; Wei-Hsian Yin; Hsien-Li Kao; Michael K Y Lee; Fabio Enrique Posas; Mann Chandavimol; Wacin Buddhari; Timothy C Dy; Ngoc Quang Nguyen; Won Jang Kim; Kiyuk Chang; Mao-Shin Lin; Yat-Yin Lam; Hung Manh Pham; Shaiful Azmi Yahaya; Kay Woon Ho; Wenzhi Pan; Xian-Bao Liu; Jian'an Wang; Hyo Soo Kim; Mao Chen
Journal:  Open Heart       Date:  2021-01

4.  Large-bore arterial access closure after transcatheter aortic valve replacement: a systematic review and network meta-analysis.

Authors:  Claudio Montalto; Andrea Raffaele Munafò; Luca Arzuffi; Francesco Soriano; Antonio Mangieri; Stefano Nava; Giovanni Luigi De Maria; Francesco Burzotta; Fabrizio D'Ascenzo; Antonio Colombo; Azeem Latib; Jacopo Andrea Oreglia; Adrian P Banning; Italo Porto; Gabriele Crimi
Journal:  Eur Heart J Open       Date:  2022-08-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.